Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)

Area of Science:

• Psychiatry and Pharmacology
• Clinical Trial Analysis
• Evidence-Based Medicine

Background:

• Haloperidol is a widely accessible antipsychotic for psychosis-induced aggression, particularly in resource-limited settings.
• Its efficacy as a sole agent for managing acute agitation and aggression in psychosis requires thorough investigation.

Purpose of the Study:

• To evaluate the effectiveness of haloperidol, administered via oral, intramuscular, or intravenous routes, as a standalone treatment for psychosis-induced agitation or aggression.
• To compare haloperidol's efficacy and safety against various control treatments and alternative medications.

Main Methods:

• Systematic review and meta-analysis of 32 randomized controlled trials (RCTs) sourced from the Cochrane Schizophrenia Group Trials Register.
• Included studies involved patients with psychosis-induced agitation/aggression, comparing haloperidol alone against other interventions.
• Primary outcomes assessed included rapid tranquilization, need for repeated treatment, specific aggressive behaviors, and adverse effects.

Main Results:

• Haloperidol promoted sleep compared to placebo but was associated with a high incidence of dystonia.
• Compared to aripiprazole, haloperidol required fewer injections, but dystonia remained a significant adverse effect.
• Haloperidol alone showed higher rates of adverse effects and acute dystonia compared to haloperidol with promethazine.

Conclusions:

• Sole intramuscular haloperidol may be life-saving in emergencies where no alternatives exist, but its use in coerced situations is ethically questionable.
• Adding sedating agents like promethazine to haloperidol is supported by evidence, while adding benzodiazepines lacks strong support and carries risks.
• Further high-quality, real-world trials are needed to clarify haloperidol's role in emergency rapid tranquilization.